Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Background - Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 2023
|
| In: |
European journal of cancer
Year: 2023, Volume: 186, Pages: 185-195 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.02.016 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.02.016 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923001089 
|
| Author Notes: | Dung T. Le, Luis A. Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1856329755 | ||
| 003 | DE-627 | ||
| 005 | 20240329080240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230816s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.02.016 |2 doi | |
| 035 | |a (DE-627)1856329755 | ||
| 035 | |a (DE-599)KXP1856329755 | ||
| 035 | |a (OCoLC)1425212744 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Le, Dung T. |e VerfasserIn |0 (DE-588)1299392806 |0 (DE-627)1856331296 |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer |b final analysis of KEYNOTE-164 |c Dung T. Le, Luis A. Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André |
| 264 | 1 | |c June 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 24. Februar 2023, Artikelversion: 2. Mai 2023 | ||
| 500 | |a Gesehen am 16.08.2023 | ||
| 520 | |a Background - Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are presented. - Methods - Eligible patients had unresectable or metastatic MSI-H/dMMR CRC and ≥2 prior systemic therapies (cohort A) or ≥1 prior systemic therapy (cohort B). Patients received pembrolizumab 200mg intravenously every 3 weeks for ≤35 cycles. The primary end-point was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 by blinded independent central review. Secondary end-points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety and tolerability. - Results - Sixty-one patients in cohort A and 63 patients in cohort B were enroled; median follow-up was 62.2 months and 54.4 months, respectively. ORR was 32.8% (95% CI, 21.3%-46.0%) in cohort A and 34.9% (95% CI, 23.3%-48.0%) in cohort B. Median DOR was not reached (NR) in either cohort. Median PFS was 2.3 months (95% CI, 2.1-8.1) in cohort A and 4.1 months (95% CI, 2.1-18.9) in cohort B. Median OS was 31.4 months (95% CI, 21.4-58.0) in cohort A and 47.0 months (95% CI, 19.2-NR) in cohort B. No new safety signals were observed. Nine patients who initially responded experienced disease progression off therapy and received second-course pembrolizumab. Six patients (66.7%) completed an additional 17 cycles of pembrolizumab, and 2 patients achieved a partial response. - Conclusions - Pembrolizumab continued to show durable antitumor activity, prolonged OS, and manageable safety in patients with previously treated MSI-H/dMMR CRC. - Clinical Trial Registry Information - ClinicalTrials.gov, NCT02460198 | ||
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Microsatellite instability | |
| 650 | 4 | |a Mismatch repair | |
| 650 | 4 | |a Pembrolizumab | |
| 700 | 1 | |a Diaz, Luis A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, Tae Won |e VerfasserIn |4 aut | |
| 700 | 1 | |a Van Cutsem, Eric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geva, Ravit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Hara, Hiroki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burge, Matthew |e VerfasserIn |4 aut | |
| 700 | 1 | |a O’Neil, Bert H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kavan, Petr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yoshino, Takayuki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guimbaud, Rosine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taniguchi, Hiroya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Élez, Elena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Al-Batran, Salah-Eddin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boland, Patrick M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cui, Yi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leconte, Pierre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marinello, Patricia |e VerfasserIn |4 aut | |
| 700 | 1 | |a André, Thierry |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 186(2023) vom: Juni, Seite 185-195 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer final analysis of KEYNOTE-164 |
| 773 | 1 | 8 | |g volume:186 |g year:2023 |g month:06 |g pages:185-195 |g extent:11 |a Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer final analysis of KEYNOTE-164 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2023.02.016 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804923001089 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230816 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 50000 |e 50000PJ1032507535 |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1856329755 |e 4366671832 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Dung T.","role":"aut","display":"Le, Dung T.","family":"Le"},{"display":"Diaz, Luis A.","family":"Diaz","role":"aut","given":"Luis A."},{"display":"Kim, Tae Won","family":"Kim","role":"aut","given":"Tae Won"},{"display":"Van Cutsem, Eric","family":"Van Cutsem","given":"Eric","role":"aut"},{"role":"aut","given":"Ravit","display":"Geva, Ravit","family":"Geva"},{"given":"Dirk","role":"aut","display":"Jäger, Dirk","family":"Jäger"},{"given":"Hiroki","role":"aut","family":"Hara","display":"Hara, Hiroki"},{"display":"Burge, Matthew","family":"Burge","given":"Matthew","role":"aut"},{"role":"aut","given":"Bert H.","display":"O’Neil, Bert H.","family":"O’Neil"},{"role":"aut","given":"Petr","family":"Kavan","display":"Kavan, Petr"},{"display":"Yoshino, Takayuki","family":"Yoshino","role":"aut","given":"Takayuki"},{"role":"aut","given":"Rosine","family":"Guimbaud","display":"Guimbaud, Rosine"},{"display":"Taniguchi, Hiroya","family":"Taniguchi","given":"Hiroya","role":"aut"},{"given":"Elena","role":"aut","family":"Élez","display":"Élez, Elena"},{"role":"aut","given":"Salah-Eddin","family":"Al-Batran","display":"Al-Batran, Salah-Eddin"},{"family":"Boland","display":"Boland, Patrick M.","given":"Patrick M.","role":"aut"},{"family":"Cui","display":"Cui, Yi","role":"aut","given":"Yi"},{"given":"Pierre","role":"aut","family":"Leconte","display":"Leconte, Pierre"},{"given":"Patricia","role":"aut","family":"Marinello","display":"Marinello, Patricia"},{"family":"André","display":"André, Thierry","given":"Thierry","role":"aut"}],"id":{"eki":["1856329755"],"doi":["10.1016/j.ejca.2023.02.016"]},"recId":"1856329755","relHost":[{"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"language":["eng"],"part":{"text":"186(2023) vom: Juni, Seite 185-195","extent":"11","volume":"186","pages":"185-195","year":"2023"},"titleAlt":[{"title":"EJC online"}],"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"pubHistory":["28.1992 -"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","dateIssuedDisp":"1992-"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer final analysis of KEYNOTE-164European journal of cancer","recId":"266883400","id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]}}],"name":{"displayForm":["Dung T. Le, Luis A. Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André"]},"physDesc":[{"extent":"11 S.","noteIll":"Illustrationen"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online verfügbar: 24. Februar 2023, Artikelversion: 2. Mai 2023","Gesehen am 16.08.2023"],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"June 2023"}],"title":[{"subtitle":"final analysis of KEYNOTE-164","title_sort":"Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer","title":"Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer"}]} | ||
| SRT | |a LEDUNGTDIAPEMBROLIZU2023 | ||